ChiCTR1900021418 版本V1.0 版本创建时间2019/02/24 18:01:58 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900021418 

最近更新日期:

Date of Last Refreshed on:

2019-02-20 22:31:31 

注册时间:

Date of Registration:

2019-02-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

超声引导下体外冲击波联合小针刀治疗腱鞘囊肿的临床疗效分析

Public title:

Ultrasound-guided extracorporeal shock wave combined with small needle knife in the treatment of tenosynovial cyst

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下体外冲击波联合小针刀治疗腱鞘囊肿

Scientific title:

Ultrasound-guided extracorporeal shock wave combined with small needle knife in the treatment of tenosynovial cyst

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李宝林 

研究负责人:

李宝林 

Applicant:

Baolin Li 

Study leader:

Baolin Li 

申请注册联系人电话:

Applicant telephone:

+86 18249514430

研究负责人电话:

Study leader's
telephone:

+86 18249514430

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

libaol@163.com

研究负责人电子邮件:

Study leader's E-mail:

libaol@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

哈尔滨市道里区地段街151号

研究负责人通讯地址:

哈尔滨市道里区地段街151号

Applicant address:

151 Diduan Street, Daoli District, Harbin, Heilongjiang, China

Study leader's address:

151 Diduan Street, Daoli District, Harbin, Heilongjiang, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

哈尔滨市第一医院

Applicant's institution:

The First Hospital of Harbin City

研究负责人所在单位:

哈尔滨市第一医院

Affiliation of the Leader:

The First Hospital of Harbin City

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20190027

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

哈尔滨市医学科学研究院

Name of the ethic committee:

Harbin Medical Science Research Institute

伦理委员会批准日期:

Date of approved by ethic committee:

2019-01-08 00:00:00

伦理委员会联系人:

李卫

Contact Name of the ethic committee:

Wei Li

伦理委员会联系地址:

哈尔滨市道里区地段街151号

Contact Address of the ethic committee:

151 Diduan Street, Daoli District, Harbin, Heilongjiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

哈尔滨市第一医院

Primary sponsor:

The First Hospital of Harbin City

研究实施负责(组长)单位地址:

哈尔滨市道里区地段街151号

Primary sponsor's address:

151 Diduan Street, Daoli District, Harbin, Heilongjiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江省

市(区县):

哈尔滨市

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

哈尔滨市第一医院

具体地址:

哈尔滨市道里区地段街151号

Institution
hospital:

The First Hospital of Harbin City

Address:

151 Diduan Street, Daoli District

经费或物资来源:

自筹

Source(s) of funding:

Self-finance

研究疾病:

腱鞘囊肿  

Target disease:

Ganglion

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

单臂 

Study design:

Single arm 

研究目的:

我们将应用肌骨超声引导下的放散式冲击波治疗腕背侧腱鞘囊肿,观察超声引导下体外冲击波联合小针刀治疗腕背侧腱鞘囊肿的临床疗效,以期为腕背侧腱鞘囊肿的治疗提供快速、有效、安全的治疗方法。  

Objectives of Study:

We will observe the clinical effect of ultrasound-guided extracorporeal shock wave combined with small needle knife in the treatment of dorsal carpal tenosynovial cysts, in order to provide a rapid, effective and safe treatment for dorsal carpal tenosynovial cysts.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①符合手腕背侧腱鞘囊肿的临床诊断标准;②年龄15~70岁之间,性别不限;③超声检查可见无回声病灶;④患者在近3个月内未接受过保守治疗或非手术治疗;⑤患者已签署知情同意书。

Inclusion criteria

(1) According to the clinical diagnostic criteria of dorsal tenosynovial cyst of the wrist;
(2) between 15 and 70 years of age, male and female;
(3) no echo lesions can be seen by ultrasound;
(4) patients have not received conservative or non-surgical treatment in the past three months;
(5) patients have signed the informed consent.

排除标准:

①严重认知障碍和精神性疾病的患者;②有利多卡因过敏史;③有出血性疾病及存在血栓的患者;④局部存在感染的患者;⑤在3月内参加过其他试验研究;⑥在3周内进行过局部注射治疗;⑦孕妇。

Exclusion criteria:

(1) Patients with severe cognitive impairment and psychiatric disorders;
(2) history of lidocaine allergy;
(3) patients with hemorrhagic diseases and thrombosis;
(4) patients with local infection;
(5) participated in other experimental studies within 3 months;
(6) local injection within 3 weeks;
(7) pregnant women.

研究实施时间:

Study execute time:

From 2019-02-25 00:00:00 To 2019-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-02-25 00:00:00 To 2019-03-31 00:00:00

干预措施:

Interventions:

组别:

治疗组

样本量:

30

Group:

Case series

Sample size:

干预措施:

超声引导下体外冲击波联合小针刀治疗

干预措施代码:

Intervention:

Ultrasound-guided extracorporeal shock wave combined with small needle knife therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

黑龙江省 

市(区县):

哈尔滨市 

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

哈尔滨市第一医院 

单位级别:

三甲 

Institution
hospital:

The First Hospital of Harbin City

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

Visual analog scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 15 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

大会公开学习

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Open Learning at the Conference

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理是基于组件化电子病历报告表(e-CRF)的临床试验信息化系统,解决了医学术语功能化设计、电子病历报告表(e-CRF)的组件化设计、数据准确性自动约束、可视化留痕、不同地域间协同实验的无缝对接等项难题,提高了数据采集的质量和效率。在不同地域间实现了数据电子化采集,缩短了临床试验数据的采集周期,将现代化的WEB技术引进了医药研发领域,突破了新药研发过程中重要的限制性环节。在管理后台的WEB页面上实现了同时具有灵活性、严密性、易用性和人性化四大特点的e-CRF设计工具;针对临床试验过程业务逻辑的半结构化特点,实现了用户实践需要(或经验需要)和系统算法之间的数据交换功能;跨部门跨区域整合、多实验并行管理与状态明细跟踪、数据检查与质疑、数据导出格式控制以及为确保数据安全所进行的相关设计等。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data acquisition and management is a clinical trial information system based on Component Electronic Medical Record Reporting Form (e-CRF). It solves such problems as functional design of medical terminology, component design of Electronic Medical Record Reporting Form (e-CRF), automatic constraints on data accuracy, visual traces, seamless docking of collaborative experiments between different regions, and improves the quality and efficiency of data acquisition. Electronic data acquisition has been realized in different regions, shortening the period of clinical trial data acquisition, introducing modern WEB technology into the field of pharmaceutical research and development, and breaking through the important restrictive links in the process of new drug research and development. E-CRF design tools with four characteristics of flexibility, rigor, ease of use and humanization are implemented on WEB pages of management background; data exchange between user practice needs (or experience needs) and system algorithms is realized according to the semi-structured characteristics of business logic of clinical trial process; cross-sectoral and cross-regional integration, multi-experiment parallel management and detailed state are realized. Tracking, data checking and querying, data export format control and related design to ensure data security.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-02-20 22:31:32